Role of Target Specific Oral Anticoagulation After Operative Management of Venous Thoracic Outlet Syndrome

Authors

Jeontaik Kwon, MD, Division of Vascular and Endovascular Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USAFollow
Paul J. DiMuzio, MD, Department of Surgery, Thomas Jefferson UniversityFollow
Babak Abai, MD, Division of Vascular and Endovascular Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USAFollow
Dawn Salvatore, MD, Division of Vascular and Endovascular Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USAFollow
Taki Galanis, MD, Thomas Jefferson UniversityFollow
Geno J. Merli, MD, Thomas Jefferson UniversityFollow
Luis H. Eraso, MD, Division of Vascular and Endovascular Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USAFollow

Files

Description

Background:

The purpose of this study is to review the efficacy of Target Specific Oral Anticoagulants (TSOAC) versus vitamin K antagonist (VKA) for post-surgical anticoagulation in patient with primary subclavian vein thrombosis. Rivaroxaban, a factor Xa inhibitor, was the first TSOAC approved by the FDA in 2012 for the treatment and prevention of deep vein thrombosis. However, the efficacy and safety of TSOAC for prevention of recurrent deep vein thrombosis after revascularization of upper extremity compression syndromes is largely unknown.

Publication Date

5-16-2016

Keywords

Role of Target Specific Oral Anticoagulation After Operative Management of Venous Thoracic Outlet Syndrome, Thomas Jefferson University, poster

Disciplines

Urology

Comments

Poster presented at: Metropolitan Chapter of AES.

Recommended Citation

Kwon, MD, Jeontaik; DiMuzio, MD, Paul J.; Abai, MD, Babak; Salvatore, MD, Dawn; Galanis, MD, Taki; Merli, MD, Geno J.; and Eraso, MD, Luis H., "Role of Target Specific Oral Anticoagulation After Operative Management of Venous Thoracic Outlet Syndrome" (2016). Department of Surgery Posters. 2.
https://jdc.jefferson.edu/surgeryposters/2